Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) is projected to announce its earnings results before the market opens on Wednesday, February 5th. Analysts expect the company to announce earnings of ($1.16) per share and revenue of $17.25 million for the quarter.
Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) last released its earnings results on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by ($0.20). Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%. The business had revenue of $14.60 million for the quarter, compared to analyst estimates of $17.99 million. During the same quarter in the previous year, the firm posted ($1.33) EPS. The business’s revenue for the quarter was down 22.8% on a year-over-year basis. On average, analysts expect Enanta Pharmaceuticals to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.
Enanta Pharmaceuticals Trading Down 3.4 %
NASDAQ ENTA opened at $5.12 on Wednesday. The stock has a market capitalization of $108.49 million, a price-to-earnings ratio of -0.93 and a beta of 0.56. The business’s 50 day moving average is $6.65 and its two-hundred day moving average is $10.33. Enanta Pharmaceuticals has a 12-month low of $4.71 and a 12-month high of $17.80.
Insider Buying and Selling at Enanta Pharmaceuticals
Analyst Upgrades and Downgrades
A number of equities research analysts recently weighed in on the company. HC Wainwright lowered their price target on Enanta Pharmaceuticals from $27.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, December 24th. Robert W. Baird lowered their price target on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a report on Tuesday, November 26th. Finally, JMP Securities restated a “market outperform” rating and issued a $21.00 price target (down previously from $22.00) on shares of Enanta Pharmaceuticals in a report on Tuesday, November 26th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $17.25.
View Our Latest Analysis on Enanta Pharmaceuticals
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.
Featured Stories
- Five stocks we like better than Enanta Pharmaceuticals
- Short Selling – The Pros and Cons
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- Consumer Staples Stocks, Explained
- What Does the Future Hold for Eli Lilly?
- How to Calculate Stock Profit
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.